+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Pediatric Drugs and Vaccines - Global Strategic Business Report

  • PDF Icon

    Report

  • 292 Pages
  • April 2025
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 1824138
The global market for Pediatric Drugs and Vaccines was valued at US$111.4 Billion in 2024 and is projected to reach US$156.7 Billion by 2030, growing at a CAGR of 5.9% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Pediatric Drugs and Vaccines - Key Trends and Drivers

The growth in the pediatric drugs and vaccines market is driven by several factors. Technological advancements in drug formulation and delivery systems are enabling the development of more effective and child-friendly medications, such as chewable tablets and dissolvable strips. The rising incidence of chronic diseases in children, including asthma, diabetes, and epilepsy, is fueling demand for long-term therapeutic solutions. Increasing awareness among parents and caregivers about the importance of timely vaccinations and preventive healthcare measures is leading to higher immunization rates. Additionally, government initiatives and funding for pediatric healthcare programs are providing a significant boost to market growth. The expanding scope of pediatric clinical trials, driven by regulatory incentives, is accelerating the introduction of new and innovative treatments. Lastly, the global focus on eradicating infectious diseases through vaccination campaigns is propelling the development and distribution of pediatric vaccines, ensuring better health outcomes for children worldwide.

Several trends and innovations are shaping the landscape of pediatric drugs and vaccines. One significant trend is the increasing emphasis on personalized medicine, which tailors treatments based on the genetic makeup of individual patients, thus improving therapeutic outcomes and minimizing adverse effects. Advances in biotechnology are leading to the development of novel vaccine platforms, such as mRNA vaccines, which have gained prominence during the COVID-19 pandemic. These platforms offer the potential for rapid development and high efficacy. Additionally, there is a growing focus on combination vaccines, which protect against multiple diseases with a single injection, thereby improving compliance and coverage rates. The integration of digital health technologies, including mobile health applications and telemedicine, is enhancing patient management and adherence to treatment regimens. Moreover, global health initiatives and partnerships are instrumental in increasing access to essential vaccines and medications in low - and middle-income countries.

Pediatric drugs and vaccines represent a crucial segment in the pharmaceutical industry, dedicated to the health and wellbeing of children from infancy through adolescence. These medications and immunizations are specifically formulated to address the unique physiological needs of young patients, ensuring safety, efficacy, and appropriate dosing. Pediatric drugs cover a broad spectrum of therapeutic areas, including infectious diseases, chronic illnesses, nutritional deficiencies, and acute conditions. Vaccines play an equally vital role by providing immunity against a range of potentially life-threatening diseases such as measles, mumps, rubella, polio, and more. The development and approval process for pediatric drugs and vaccines involve rigorous clinical trials and regulatory scrutiny to ensure they meet stringent safety standards, given the vulnerable nature of the patient population.

Report Scope

The report analyzes the Pediatric Drugs and Vaccines market, presented in terms of market value (USD). The analysis covers the key segments and geographic regions outlined below.

Segments

Technology (Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid, Other Technologies); Product Type (Vaccines, Drugs).

Geographic Regions/Countries

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Conjugate Technology segment, which is expected to reach US$52 Billion by 2030 with a CAGR of a 7%. The Live Attenuated Technology segment is also set to grow at 6% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, valued at $29.6 Billion in 2024, and China, forecasted to grow at an impressive 9.7% CAGR to reach $35.4 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Pediatric Drugs and Vaccines Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Pediatric Drugs and Vaccines Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Pediatric Drugs and Vaccines Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as Abbott Laboratories, Allergan Inc., Amgen Inc., AstraZeneca Plc, Boehringer Ingelheim GmbH and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 76 companies featured in this Pediatric Drugs and Vaccines market report include:

  • Abbott Laboratories
  • Allergan Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Genentech Inc.
  • GlaxoSmithKline Plc
  • Janssen Biologics B.V
  • Merck & Co. Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi
  • Shionogi Inc.
  • Shire Pharmaceuticals Group Plc

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • Global Economic Update
  • Pediatric Drugs and Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Increasing Incidence of Chronic Pediatric Diseases Throws the Spotlight on Long-Term Therapeutic Solutions
  • Advancements in Drug Formulation Propel Growth in Pediatric Medications Market
  • Rising Awareness about Preventive Healthcare Expands Addressable Market Opportunity for Pediatric Vaccines
  • Innovations in Vaccine Platforms Strengthen Business Case for Next-Generation Immunizations
  • Government Initiatives and Funding Generates Demand for Pediatric Healthcare Programs
  • Integration of Digital Health Technologies Drives Adoption of Advanced Patient Management Tools
  • Combination Vaccines Accelerate Demand by Improving Compliance and Coverage Rates
  • Global Health Initiatives Ensure Increasing Access to Essential Pediatric Vaccines
  • Personalized Medicine Enhances Therapeutic Outcomes for Pediatric Patients
  • Advances in Drug Delivery Systems Sustain Growth in Pediatric Drug Administration
  • Expansion of Telemedicine Services Drives Adoption of Remote Pediatric Care Solutions
  • Rising Investment in Biotechnology Generates Opportunities for Novel Pediatric Treatments
  • Increasing Focus on Eradicating Infectious Diseases Propels Growth in Pediatric Vaccination Programs
  • Enhanced Safety and Efficacy Standards Generate Confidence in Pediatric Drug and Vaccine Adoption
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Pediatric Drugs and Vaccines Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • Table 2: World Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 3: World Historic Review for Pediatric Drugs and Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 4: World 15-Year Perspective for Pediatric Drugs and Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • Table 5: World Recent Past, Current & Future Analysis for Conjugate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 6: World Historic Review for Conjugate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 7: World 15-Year Perspective for Conjugate by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 8: World Recent Past, Current & Future Analysis for Live Attenuated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 9: World Historic Review for Live Attenuated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 10: World 15-Year Perspective for Live Attenuated by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 11: World Recent Past, Current & Future Analysis for Inactivated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 12: World Historic Review for Inactivated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 13: World 15-Year Perspective for Inactivated by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 14: World Recent Past, Current & Future Analysis for Subunit by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 15: World Historic Review for Subunit by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 16: World 15-Year Perspective for Subunit by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 17: World Recent Past, Current & Future Analysis for Toxoid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 18: World Historic Review for Toxoid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 19: World 15-Year Perspective for Toxoid by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 20: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 21: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 22: World 15-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 23: World Recent Past, Current & Future Analysis for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 24: World Historic Review for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 25: World 15-Year Perspective for Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 26: World Recent Past, Current & Future Analysis for Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 27: World Historic Review for Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 28: World 15-Year Perspective for Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Pediatric Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • Table 29: USA Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 30: USA Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 31: USA 15-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2015, 2025 & 2030
  • Table 32: USA Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 33: USA Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 34: USA 15-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2015, 2025 & 2030
CANADA
  • Table 35: Canada Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 36: Canada Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 37: Canada 15-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2015, 2025 & 2030
  • Table 38: Canada Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 39: Canada Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 40: Canada 15-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2015, 2025 & 2030
JAPAN
  • Pediatric Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • Table 41: Japan Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 42: Japan Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 43: Japan 15-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2015, 2025 & 2030
  • Table 44: Japan Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 45: Japan Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 46: Japan 15-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2015, 2025 & 2030
CHINA
  • Pediatric Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • Table 47: China Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 48: China Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 49: China 15-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2015, 2025 & 2030
  • Table 50: China Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 51: China Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 52: China 15-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2015, 2025 & 2030
EUROPE
  • Pediatric Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • Table 53: Europe Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 54: Europe Historic Review for Pediatric Drugs and Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 55: Europe 15-Year Perspective for Pediatric Drugs and Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • Table 56: Europe Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 57: Europe Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 58: Europe 15-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2015, 2025 & 2030
  • Table 59: Europe Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 60: Europe Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 61: Europe 15-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2015, 2025 & 2030
FRANCE
  • Pediatric Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • Table 62: France Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 63: France Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 64: France 15-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2015, 2025 & 2030
  • Table 65: France Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 66: France Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 67: France 15-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2015, 2025 & 2030
GERMANY
  • Pediatric Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • Table 68: Germany Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 69: Germany Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 70: Germany 15-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2015, 2025 & 2030
  • Table 71: Germany Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 72: Germany Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 73: Germany 15-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2015, 2025 & 2030
ITALY
  • Table 74: Italy Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 75: Italy Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 76: Italy 15-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2015, 2025 & 2030
  • Table 77: Italy Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 78: Italy Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 79: Italy 15-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2015, 2025 & 2030
UNITED KINGDOM
  • Pediatric Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • Table 80: UK Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 81: UK Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 82: UK 15-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2015, 2025 & 2030
  • Table 83: UK Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 84: UK Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 85: UK 15-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2015, 2025 & 2030
SPAIN
  • Table 86: Spain Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 87: Spain Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 88: Spain 15-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2015, 2025 & 2030
  • Table 89: Spain Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 90: Spain Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 91: Spain 15-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2015, 2025 & 2030
RUSSIA
  • Table 92: Russia Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 93: Russia Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 94: Russia 15-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2015, 2025 & 2030
  • Table 95: Russia Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 96: Russia Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 97: Russia 15-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2015, 2025 & 2030
REST OF EUROPE
  • Table 98: Rest of Europe Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 99: Rest of Europe Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 100: Rest of Europe 15-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2015, 2025 & 2030
  • Table 101: Rest of Europe Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 102: Rest of Europe Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 103: Rest of Europe 15-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2015, 2025 & 2030
ASIA-PACIFIC
  • Pediatric Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • Table 104: Asia-Pacific Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 105: Asia-Pacific Historic Review for Pediatric Drugs and Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 106: Asia-Pacific 15-Year Perspective for Pediatric Drugs and Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • Table 107: Asia-Pacific Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 108: Asia-Pacific Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 109: Asia-Pacific 15-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2015, 2025 & 2030
  • Table 110: Asia-Pacific Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 111: Asia-Pacific Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 112: Asia-Pacific 15-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2015, 2025 & 2030
AUSTRALIA
  • Pediatric Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
INDIA
  • Pediatric Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Pediatric Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Pediatric Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Pediatric Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abbott Laboratories
  • Allergan Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Genentech Inc.
  • GlaxoSmithKline Plc
  • Janssen Biologics B.V
  • Merck & Co. Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi
  • Shionogi Inc.
  • Shire Pharmaceuticals Group Plc

Table Information